Csaba Poroszlai is confirmed CEO of the company by the Board of Directors of Egis. Balázs Vándor is appointed to the position of the Company’s Chief Financial Officer.

Following the success of Egis Russia and Egis Polska, we are proud to announce that Egis Praha has also been recognized as Best Employer at Aon Hewitt’s Employee Engagement Survey.

Egis has developed a new procedure for the dehalogenation of technological wastewaters. In 2018, the Swedish Chamber of Commerce in Hungary recognized the innovation with the Gran Prize Interdisciplinary Innovative award.

Hungarian-based Egis Pharmaceuticals PLC signed an exclusive distribution agreement with Mundipharma network for a pegfilgrastim biosimilar. Pursuant to the agreement, Egis gains the exclusive distribution rights related to the medicine used to reduce a common side effect of cancer treatment called neutropenia and the related life-threatening infections. Thus, Egis gets the opportunity to launch this pegfilgrastim biosimilar product in four Eastern European countries.

PharmaBoardroom is a site for senior professionals, providing global news, trends and reports relating to the pharmaceutical industry.

EGIS Polska team among 5 winners of the first edition of International Digital Idea Challenge EGIS.

May this joyful season of Easter fill your heart with renewed hope, love and peace. Happy Easter!

The predecessor of Egis Pharmaceuticals PLC, Dr Wander Pharmaceuticals and Nutriments Ltd. was registered on 19 February 1913.

May the spirit of Christmas bring you peace, love and happiness. Merry Christmas and Happy New Year!

We are pleased to announce that EGIS Poland has joined the "Operation Clean River" project. Operation Clean River is the largest nationwide action of cleaning up coastal areas.